Senolytics, targeting dysfunctional cells, hold promise for longevity but remain underrepresented in consumer products.
Walk into any health store or browse any longevity forum, and the conversation is dominated by a handful of molecules. NAD+ precursors like NMN and NR have become the flagship category of the longevity supplement market, driven by high-profile advocates and a steady stream of published research. They are, by most measures, the first generation of consumer longevity products to gain mainstream traction.
But among the twelve recognized hallmarks of aging — the biological mechanisms that drive how and why we age — NAD+ decline is just one. Another hallmark, cellular senescence, has generated enormous scientific interest over the past decade. Yet when it comes to consumer products, the category barely exists.
A research field without a market
Cellular senescence — the accumulation of dysfunctional zombie cells that no longer divide but refuse to die — has been one of the most actively studied areas in aging biology since the publication of the hallmarks framework. Researchers at Mayo Clinic, MIT and other leading institutions have mapped how these cells drive chronic inflammation, burden the immune system and contribute to age-related decline.
Compounds that target senescent cells — known as senolytics — have shown striking results in preclinical studies. A widely cited 2018 paper in EBioMedicine compared ten naturally occurring flavonoids for their senolytic potential, identifying fisetin as one of the most effective. Clinical trials are now underway.
So why hasn’t the consumer market caught up?
Part of the answer is structural. NAD+ supplements are taken daily, which fits the existing supplement model — a bottle, a routine, a monthly subscription. Senolytics work differently. The research points toward intermittent dosing: short, intensive interventions followed by rest. That’s a harder product to sell, and a harder model to build a subscription business around.
The other part is timing. NAD+ research had a head start in the consumer space, propelled by prominent researchers with public platforms. Senolytics, despite a comparable body of scientific literature, simply hasn’t had the same commercial catalyst — until recently.
Bridging the gap
Swedish longevity company Lifeseeds is among the first in Europe to bring a dedicated senolytic product to market. Their supplement, Zenith, combines high-dose fisetin (1,400 mg) with quercetin (500 mg), piper longum for bioavailability, and zinc for immune support. It follows an intermittent protocol — six capsules daily for two consecutive days per month — designed to mirror the dosing approach used in clinical senolytic research.
“Senolytics is probably the most underdeveloped consumer category in the longevity space,” says Mathias Lobendahl, founder of Lifeseeds. “The research has been there for years. The clinical trials are running. But almost no one has translated it into an actual product that people can use. That gap is what we’re trying to close.”
Lifeseeds already produces Nexus, an NAD+ supplement, and Neuro, a cognitive health product. Lobendahl describes Zenith as a natural extension of the company’s approach: building products around distinct hallmarks of aging rather than chasing broad-spectrum formulas.
“Every product we make targets a specific mechanism of aging,” Lobendahl explains. “Nexus addresses NAD+ decline. Neuro targets neurological aging. With Zenith, we’re addressing cellular senescence. These aren’t general wellness products — they’re built around the actual biology of why we age.”
An emerging category
Whether consumer senolytics follow the trajectory of NAD+ remains to be seen. The science is still maturing, and the field faces the same challenge that any emerging supplement category does: translating preclinical promise into real-world relevance without overstepping what the evidence supports.
But the building blocks are in place. The research base is large and growing. The hallmarks framework gives the category scientific grounding. And the first products are entering the market — not as theoretical concepts, but as formulated supplements with specific ingredients, specific doses, and protocols grounded in published literature.
For a field that has spent years as one of the most studied and least commercialized areas in aging biology, that shift may be long overdue.
Sources: López-Otín et al., “Hallmarks of Aging: An Expanding Universe,” Cell, 2023. Zhu et al., “New agents that target senescent cells,” EBioMedicine, 2018. Kirkland & Tchkonia, Mayo Clinic, 2017.
